Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

HalioDx S.A.S.. (5/22/18). "Press Release: HalioDx Signs an Agreement with Everything Genetic to Make Immunoscore Colon Assay Available in the United Kingdom". Marseille.

Region Region United Kingdom (GB)
Organisations Organisation HalioDx S.A.S.
  Organisation 2 Everything Genetic Ltd.
Products Product Immunoscore® cancer prognosis tool
  Product 2 clinical genomic test (nucleic acid diagnostics)
Persons Person Fert, Vincent (HalioDx 201503– CEO + CO-founder before Ipsogen 200708– President + CEO)
  Person 2 Price, James Stephen Andrew (Everything Genetic Ltd 201805 CEO + Founder)
     


HalioDx SAS, an immuno-oncology diagnostic company, announced today that Everything Genetic Ltd. will market and distribute Immunoscore® Colon assay in the United Kingdom.

Oncologists and patients in the UK will have access to Immunoscore® Colon, a unique diagnostic assay that predicts the risk of recurrence of patients with early stage colon cancer. Immunoscore® Colon combines tissue diagnostic and advanced image analysis technologies to quantify T-cells which infiltrate both the core of the colon tumor and its invasive margin. The assay guides oncologists to decide on critical therapeutic options in stages II and stage III colon cancers1. It is the very first IVD assay of the HalioDx Immunoscore® pipeline, leveraging image analysis technology to enhance clinical utility and standardization.

“There are 30 000 new cases of Colon Cancer per year in the UK2. For half of these patients, treatment decisions are problematic leading to over or under treatments. Thanks to Immunoscore® Colon, relapse risk assessment will be improved for these patients,” says Vincent Fert CEO of HalioDx. He added “We are delighted to collaborate with Everything Genetic Ltd., an expert company enabling UK oncologists and patients to access value-based diagnostic solutions.”

James Price, CEO of Everything Genetic Ltd, the distributor of HalioDx’s products in the UK, comments: "We are delighted to be working with HalioDx to provide its diagnostics tests across the UK. By providing easy access to these tests, our collaboration offers value for money and gives patients and physicians the power to make the best possible therapeutic decisions. Reimbursement for innovative genetic profiling diagnostics tools is growing and we look forward to building on our partnership with HalioDx to expand the offering of precision medicine tools in the UK”.

Immunoscore® Colon was discovered by Dr. Jérôme Galon and developed in compliance with the IVD standards by HalioDx. The clinical value has been validated in several studies on early stage colon cancer patients. Recently the results of the SITC International study3 conducted on more than 2600 patients have been published in The Lancet journal. The prognostic value has also been validated on 600 stage III colon cancer patients from the FOLFOX arm of the prospective NCCTG N01474 study.


About HalioDx

The Immune Response to Cancer Diagnostics

HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

Immunoscore® proprietary technology, pioneered by Jérôme Galon at the Cordeliers Research Center, Paris,

France, integrates immunohistochemistry combined with sophisticated algorithm and advanced imaging analysis enabling extraction of spatially-organized tissue molecular information. Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression. HalioDx collaborates with renowned international clinical groups to support clinical utility and ensure rigorous performance validation of its assays in selected cancer indications.

Two additional assays, Halioseek® & Immunosign®, have been developed by HalioDx and provide tools to help stratifying patients for immunotherapies.

HalioDx has an experienced team of more than 130 employees, a CLIA-certified laboratory and compliant facilities to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies. The company co-founded the European immunology cluster Marseille Immunopôle (MI).

For more information, please visit our websites www.haliodx.com and www.immunoscore-colon.com and follow the company on Twitter @HalioDx.


Contacts

HalioDx SAS
Vincent Fert
President and CEO
+ 33 (0)4 91 29 30 90
vincent.fert@haliodx.com

Everything Genetic Ltd

James Price
CEO and Founder
+44 (0) 7495 981816
james@everythinggeneticltd.co.uk
www.everythinggeneticltd.co.uk

ATCG Press

Marie Puvieux (France)
Mob: +33 (0)6 10 54 36 72
Céline Voisin (ROW)
Mob: +33 (0)6 62 12 53 39
haliodx@atcg-partners.com

Twitter: twitter.com/haliodx


1 Hermitte J Immunother Cancer 2016

2 Source: Cancer Research UK

3 Pagès et al. The Lancet 2018

4 Sinicrope et al. Oral presentation ASCO GI 2018

   
Record changed: 2018-05-23

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for HalioDx S.A.S.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSG] Life-Sciences-Germany.com – The Business Web Portal 600x80px




» top